Biologix Hair Inc. Names Thomas M. McDermott Chairman of the Board

Biologix Hair Inc. Names Thomas M. McDermott Chairman of the Board 
TORONTO, ONTARIO -- (Marketwire) -- 01/31/13 -- Biologix Hair Inc.
(OTCBB:BLGX) (OTCQB:BLGX) has appointed Thomas M. McDermott to Chair
its Board of Directors, replacing Ron Holland who will remain a
Director and the Company's Chief Executive Officer. 
Ron Holland, Biologix Director and CEO, stated, "It has always been
the intent of our management team to separate the roles and
responsibilities incumbent with each of the senior positions,
Chairman of the Board and Chief Executive Officer. I am extremely
pleased to have someone of Thom's extensive experience assume the
leadership position at the Board level and I look forward to working
closely with him and the rest of our team to maximize the future
potential of Biologix for all shareholders." 
Thomas McDermott has more than 40 years of management and executive
experience in a wide range of business and government settings, as
well as in business and political consulting. For 22 years, Tom
headed up a group of investors who owned seven radio stations in the
Chicago market and served as CEO of Northwest Indiana Forum, a group
representing the needs of large- and medium-sized industry in a
seven-county area for 12 years. 
Mr. McDermott served as mayor of Hammond, Indiana from 1983 to 1991,
the first Republican elected to that office in 29 years. As mayor, he
was CEO of the municipal government's 1200 employees and $50 million
budget. Prior to his election, Tom managed successful political
campaigns and oversaw circulation for two daily newspapers, the
Chicago Sun Times and Hammond Times. 
Tom McDermott attended Utah State and Napa College. He has received
numerous leadership and community service awards, including the
Hammond Chamber of Commerce's "Business Person of the Year," "Man of
the Year" from Greater Hammond Community Services and the Lake County
Economic Opportunity Council Service Award. 
Commenting on his appointment, newly appointed Chairman, Thomas
McDermott stated, "I am very honored to serve as the company's
Chairman and believe Biologix is uniquely positioned to capitalize on
its patent-pending breakthrough hair loss prevention and rejuvenation
therapy. Building an international business requires significant
capital resources, strong and effective management and a clear and
concise business plan that defines roles and responsibilities. I am
confident that Biologix has the core elements necessary to execute
and meet the ongoing myriad challenges that face any growing
corporation. 
"There is no better feeling than knowing you have done all you can to
contribute to the success of any organization's ability to fully
capitalize on its opportunity. And that is exactly what I intend to
do as Chairman of Biologix," continued McDermott. 
About Biologix Hair Inc. and Biologix Hair Science Ltd. 
Biologix Hair Inc. (Biologix Hair), together with its wholly owned
biotechnology subsidiary, Biologix Hair Science Ltd. (TM) (BHS), is
focused on realizing the full market potential for its patent-pending
hair loss formula - Biologix Revive - and its demonstrated ability to
prevent and reverse the effects of alopecia, which plagues hundreds
of millions worldwide. 
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial
treatments of Biologix Revive were administered to 5,000-plus
patients in South America suffering with varying degrees of alopecia,
as well as people seeking preventive treatment. The participating
treatment clinicians subjectively observed and reported that
virtually 100% of preventive care clients continued to retain their
healthy hair and an estimated 80-85% of the males and 90-plus% of the
females treated for hair regeneration experienced significant
regrowth of their own natural hair. And among alopecia areata
patients, virtually total hair regrowth was observed in 100% of the
cases. To date, no negative side effects have been reported. 
BHS is currently focused on obtaining FDA approval for its
breakthrough hair loss prevention and regeneration therapy and has
initiated a research and development program with one of the world's
leading medical research universities, the Beijing Institute of
Technology (BIT). The R&D program, expected to take approximately
twelve months to complete, is an important final step before formal
clinical trials and the FDA approval process begins. 
Additionally, on May 11, 2012, Venable LLC, the Washington-based law
firm overseeing the worldwide IP and regulatory approval processes on
behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on
behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is
an international treaty, administered by the World Intellectual
Property Organization (WIPO), to which 144 countries have as of now
contracted, including Canada and the United States. 
Biologix management is determined to be in a ready position to
capitalize on the high-margin sales potential of the Biologix Hair
Therapy System(TM), if and when FDA and other major market approvals
are forthcoming. 
As BHS advances the regulatory approval process, Biologix Hair,
together with wholly owned subsidiary companies operated by BHS, are
rapidly developing a global distribution network of licensed
clinicians and medical practitioners seeking to become Certified
Biologix Hair Therapists(TM) and secure exclusive territorial
purchasing and treatment rights for the Biologix Hair Therapy
System(TM). 
Biologix Hair has decided not to risk creating any potential
regulatory conflicts by offering treatment outside the United States
and other major high-product-margin markets until FDA approval has
been granted. Therefore, the Biologix Hair Therapy System(TM) is not
yet available other than to the 5,000+ patients who participated in
the pre-clinical-trials conducted in South America. 
To learn more about Clinician Licensing opportunities, Click Here or
call toll free +1 855.737.0333 or +1 647.344.5900. 
Disclaimer 
This announcement is not an offer to sell any Biologix Hair Inc.
("Biologix") securities. Offers for any given security are made only
through applicable offering circulars and related documents filed
with the SEC pursuant to the Securities Act of 1933 or the Securities
Exchange Act of 1934. Certain statements contained herein and
subsequent oral statements made by and on behalf of Biologix may
contain "forward-looking statements". Such forward-looking statements
are identified by words such as "intends," "anticipates," "believes,"
"expects" and "hopes" and includes, without limitation, the
development of treatment centers and approval from regulatory
authorities. Forward-looking statements express our expectations or
predictions of future events or results. They are not guarantees and
are subject to many risks and uncertainties. There are a number of
factors beyond our control that could cause actual events or results
to be significantly different from those described in the
forward-looking statements. Any or all of our forward-looking
statements in this report or in any other public statements we make
may turn out to be wrong. We undertake no obligation to publicly
update or review any forward-looking statements, whether as a result
of new information, future developments or otherwise. In Canada,
Europe and the United States, the Biologix treatment is not approved
for use by Health Canada, EMA or the FDA. The company makes no
representations that it will receive Health.
Contacts:
Biologix Hair Inc.
Corporate Communications
Toll Free: 1 855.292.8585
902.801.7920
CorporateCommunications@BiologixHair.com
www.BiologixHair.com
 
 
Press spacebar to pause and continue. Press esc to stop.